Side-by-side · Research reference

IGF-1 LR3vsMazdutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED10/58 cited

BPhase 3HUMAN-REVIEWED19/62 cited

IGF-1 LR3

IGF-1 Analogue · Research

3–10×Potency vs IGF-I

Low IGFBPBinding affinity

ResearchStatus

Research only · SQ typical in animal models

Mazdutide

GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3

9 mgWeekly doseJi 2026

12.4%Weight lossAzam 2026

Phase 3Status (China)

SQ · Abdomen · Once WeeklyJi 2026

01Mechanism of Action

Parameter

IGF-1 LR3

Mazdutide

Primary target

IGF-1 receptor (IGF-1R)McTavish 2009

GLP-1 receptor and glucagon receptorAbdul 2026 Elmendorf 2026

Pathway

IGF-1R → IRS-1 → PI3K/Akt → Cell proliferation, protein synthesis, anti-apoptosisMuhlbradt 2009

Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026 Abulehia 2026

Downstream effect

Enhanced cell proliferation, muscle anabolism, inhibition of apoptosis, increased telomerase activity

Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D

Feedback intact?

No — exogenous IGF analogue bypasses GH-mediated regulation

Yes — physiological receptor-mediated signaling preserved

Origin

Synthetic 83-AA analogue: 13-AA N-terminal extension + Arg substitution at position 3

Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity

Antibody development

—

02Dosage Protocols

Parameter

IGF-1 LR3

Mazdutide

Research dose (animal models)

Variable by protocol and species

In vivo murine atherosclerosis studies used sustained delivery.

—

In vitro typical concentration

10–1000 ng/mLThomas 2007

Dose-dependent effects on follicle growth and estradiol production.

—

Half-maximal stimulation

0.6 nM LR3 vs 1.5 nM native IGF-1Price 2004

2.5-fold greater potency in lung fibroblast proliferation.

—

Evidence basis

Animal / in vitro only

Phase 2 RCT / Phase 3 ongoingJi 2026 Luo 2026

Human use

Not FDA-approved; no published human trials

—

Phase 2 studied dose

—

9 mg / weekJi 2026

Highest efficacy dose in obesity trial (BMI ≥30 kg/m²).Ji 2026

Frequency

—

Once weeklyJi 2026 Luo 2026

Route

—

SubcutaneousJi 2026

Dose escalation

—

3 mg → 6 mg → 9 mg (titration schedule in trials)

Gradual escalation to minimize GI side effects.

Duration (trials)

—

24–48 weeks

Population

—

Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities

Phase 3 comparator

—

Semaglutide 1 mg/week (DREAMS-3 trial)Luo 2026

03Metabolic / Fat Loss Evidence

Parameter

IGF-1 LR3

Mazdutide

Mechanism

IGF-1R activation → lipolytic signaling; secondary to anabolic effects

Appetite suppression (GLP-1) + energy expenditure (glucagon)Elmendorf 2026

Direct lipolytic evidence

Minimal — primarily anabolic/anti-apoptotic in literature

—

Atherosclerotic plaque effects

Reduced stenosis and core size in ApoE-KO micevon 2011

Plaque stabilization via vSMC phenotype modulation, not direct fat loss.

—

Human data

None published

—

Percentage body weight loss

—

12.4% (pooled meta-analysis, 9 mg dose)

95% CI: -16.15% to -8.68%, random-effects model.Azam 2026

Absolute weight loss

—

9.8 kg (mean)Azam 2026

95% CI: -13.15 to -6.37 kg.Azam 2026

Responder rate (≥10% loss)

—

Not explicitly reported in available abstracts

BMI reduction

—

Significant reduction in Chinese adults BMI ≥30 kg/m²Ji 2026

Visceral fat

—

Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)

Glycemic improvement

—

HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)

Comparator efficacy

—

Head-to-head vs semaglutide 1 mg (Phase 3 pending publication)Luo 2026

Key publications

—

Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026

04Side Effects & Safety

Parameter

IGF-1 LR3

Mazdutide

Hypoglycemia risk

Theoretical — IGF-1 analogues can lower blood glucose

—

Excessive cell proliferation

Mitogenic signaling; theoretical tumor promotion risk

—

Telomerase activation

2–10-fold increase in prostate cancer cells (PC-3, DU-145, LAPC-4)Wetterau 2003

Critically involved in cancer cell immortalization.

—

Oocyte degeneration

Increased oocyte degeneration at high doses (≥1000 ng/mL) in bovine folliclesThomas 2007

—

Unregulated anabolism

Bypasses physiological GH/IGF-1 feedback; no pulsatility control

—

Unknown human safety profile

No published human trials; safety data absent

—

Gastrointestinal symptoms

—

Nausea, vomiting, diarrhea (most common, GLP-1 effect)

Injection site reactions

—

Erythema, pruritus, local discomfort

Hypoglycemia

—

Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas

Cardiovascular effects

—

Increased heart rate (glucagon effect, transient)

Pancreatitis risk

—

Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain

Thyroid C-cell tumors

—

Black box warning for GLP-1 class (rodent data); human relevance unclear

Gallbladder disease

—

Cholelithiasis, cholecystitis (rapid weight loss effect)

Tolerability

—

Generally well-tolerated; GI effects diminish with dose titration

Absolute Contraindications

IGF-1 LR3

·Active malignancy or history of cancer
·Not approved for human use

Mazdutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
·Hypersensitivity to mazdutide or excipients
·Pregnancy

Relative Contraindications

IGF-1 LR3

·Diabetes or glucose intolerance
·Family history of cancer

Mazdutide

·History of pancreatitis
·Severe gastroparesis or GI motility disorders
·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
·Renal impairment (limited data, use with caution)

05Administration Protocol

Parameter

IGF-1 LR3

Mazdutide

1. Research use only

IGF-1 LR3 is not FDA-approved for human use. All administration data derives from animal or in vitro studies.

Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.

2. Typical research route

Subcutaneous or intraperitoneal injection in animal models. In vitro: added directly to culture medium at concentrations of 10–1000 ng/mL.Thomas 2007

Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.

3. Reconstitution (research)

Lyophilised powder reconstituted in sterile water or buffered saline per manufacturer protocol. Store at 2–8 °C after reconstitution.

Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.

4. Stability

Enhanced stability vs native IGF-1 due to reduced IGFBP binding; exact half-life in vivo not fully characterized in humans.

Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.

5. Needle technique

—

Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.

06Stack Synergy

IGF-1 LR3

+ GHRP-6

Multi-pathway

View GHRP-6 →

GHRP-6 stimulates endogenous GH release, which drives hepatic IGF-1 synthesis. IGF-1 LR3 provides exogenous, IGFBP-resistant IGF signaling. Combining upstream GH stimulation with downstream IGF receptor activation creates a dual-pathway anabolic effect. However, this bypasses natural feedback and carries compounded mitogenic risk.

GHRP-6: 100–200 mcg SQ · 2–3× daily
IGF-1 LR3: Research doses variable · post-workout typical in animal models
Note: Research context only — no human protocols exist
Primary benefit: Theoretical maximal anabolic signaling (GH + IGF axes)

+ Ipamorelin

Multi-pathway

View Ipamorelin →

Ipamorelin (selective GHRP) stimulates pulsatile GH release without cortisol/prolactin elevation. IGF-1 LR3 directly activates IGF-1R independent of GH. This stack targets both upstream (GH secretion) and downstream (IGF receptor) nodes but eliminates physiological feedback, raising safety concerns around unchecked proliferation.

Ipamorelin: 200–300 mcg SQ · evening
IGF-1 LR3: Research doses only · timing variable
Caution: No human data; animal/in vitro only
Primary benefit: Dual-axis anabolic signaling (theoretical)

Mazdutide

— no documented stacks